NCT04452084
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 21 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have maximum lesion or cavity size that is less than or equal to 5cm
Exclusions: Patients with prior whole brain radiation therapy; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04452084